Copyright Reports & Markets. All rights reserved.

Global Immuno-oncology Drugs Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Immuno-oncology Drugs Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Immuno-oncology Drugs Market Size Growth Rate by Product
      • 1.4.2 Immune Checkpoint Inhibitors
      • 1.4.3 Monoclonal Antibodies
      • 1.4.4 Cytokine-Based Immunotherapy
      • 1.4.5 Cancer Vaccines
      • 1.4.6 CAR-T Cell Therapy
    • 1.5 Market by End User
      • 1.5.1 Global Immuno-oncology Drugs Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Pharmacies
      • 1.5.4 Online Pharmacies
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Immuno-oncology Drugs Market Size
      • 2.1.1 Global Immuno-oncology Drugs Revenue 2014-2025
      • 2.1.2 Global Immuno-oncology Drugs Sales 2014-2025
    • 2.2 Immuno-oncology Drugs Growth Rate by Regions
      • 2.2.1 Global Immuno-oncology Drugs Sales by Regions
      • 2.2.2 Global Immuno-oncology Drugs Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Immuno-oncology Drugs Sales by Manufacturers
      • 3.1.1 Immuno-oncology Drugs Sales by Manufacturers
      • 3.1.2 Immuno-oncology Drugs Sales Market Share by Manufacturers
      • 3.1.3 Global Immuno-oncology Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Immuno-oncology Drugs Revenue by Manufacturers
      • 3.2.1 Immuno-oncology Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Immuno-oncology Drugs Revenue Share by Manufacturers (2014-2019)
    • 3.3 Immuno-oncology Drugs Price by Manufacturers
    • 3.4 Immuno-oncology Drugs Manufacturing Base Distribution, Product Types
      • 3.4.1 Immuno-oncology Drugs Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Immuno-oncology Drugs Product Type
      • 3.4.3 Date of International Manufacturers Enter into Immuno-oncology Drugs Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Immuno-oncology Drugs Sales by Product
    • 4.2 Global Immuno-oncology Drugs Revenue by Product
    • 4.3 Immuno-oncology Drugs Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Immuno-oncology Drugs Breakdown Data by End User

    6 North America

    • 6.1 North America Immuno-oncology Drugs by Countries
      • 6.1.1 North America Immuno-oncology Drugs Sales by Countries
      • 6.1.2 North America Immuno-oncology Drugs Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Immuno-oncology Drugs by Product
    • 6.3 North America Immuno-oncology Drugs by End User

    7 Europe

    • 7.1 Europe Immuno-oncology Drugs by Countries
      • 7.1.1 Europe Immuno-oncology Drugs Sales by Countries
      • 7.1.2 Europe Immuno-oncology Drugs Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Immuno-oncology Drugs by Product
    • 7.3 Europe Immuno-oncology Drugs by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Immuno-oncology Drugs by Countries
      • 8.1.1 Asia Pacific Immuno-oncology Drugs Sales by Countries
      • 8.1.2 Asia Pacific Immuno-oncology Drugs Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Immuno-oncology Drugs by Product
    • 8.3 Asia Pacific Immuno-oncology Drugs by End User

    9 Central & South America

    • 9.1 Central & South America Immuno-oncology Drugs by Countries
      • 9.1.1 Central & South America Immuno-oncology Drugs Sales by Countries
      • 9.1.2 Central & South America Immuno-oncology Drugs Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Immuno-oncology Drugs by Product
    • 9.3 Central & South America Immuno-oncology Drugs by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Immuno-oncology Drugs by Countries
      • 10.1.1 Middle East and Africa Immuno-oncology Drugs Sales by Countries
      • 10.1.2 Middle East and Africa Immuno-oncology Drugs Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Immuno-oncology Drugs by Product
    • 10.3 Middle East and Africa Immuno-oncology Drugs by End User

    11 Company Profiles

    • 11.1 Amgen, Inc
      • 11.1.1 Amgen, Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Amgen, Inc Immuno-oncology Drugs Products Offered
      • 11.1.5 Amgen, Inc Recent Development
    • 11.2 AstraZeneca, Plc
      • 11.2.1 AstraZeneca, Plc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products Offered
      • 11.2.5 AstraZeneca, Plc Recent Development
    • 11.3 Bristol-Myers Squibb
      • 11.3.1 Bristol-Myers Squibb Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products Offered
      • 11.3.5 Bristol-Myers Squibb Recent Development
    • 11.4 Celgene Corporation
      • 11.4.1 Celgene Corporation Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Celgene Corporation Immuno-oncology Drugs Products Offered
      • 11.4.5 Celgene Corporation Recent Development
    • 11.5 Eli Lilly and Company
      • 11.5.1 Eli Lilly and Company Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Eli Lilly and Company Immuno-oncology Drugs Products Offered
      • 11.5.5 Eli Lilly and Company Recent Development
    • 11.6 Merck & Co.
      • 11.6.1 Merck & Co. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Merck & Co. Immuno-oncology Drugs Products Offered
      • 11.6.5 Merck & Co. Recent Development
    • 11.7 Hoffmann-La Roche AG
      • 11.7.1 Hoffmann-La Roche AG Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Products Offered
      • 11.7.5 Hoffmann-La Roche AG Recent Development
    • 11.8 Johnson & Johnson
      • 11.8.1 Johnson & Johnson Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Johnson & Johnson Immuno-oncology Drugs Products Offered
      • 11.8.5 Johnson & Johnson Recent Development
    • 11.9 Novartis International AG
      • 11.9.1 Novartis International AG Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Novartis International AG Immuno-oncology Drugs Products Offered
      • 11.9.5 Novartis International AG Recent Development
    • 11.10 AbbVie, Inc.
      • 11.10.1 AbbVie, Inc. Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 AbbVie, Inc. Immuno-oncology Drugs Products Offered
      • 11.10.5 AbbVie, Inc. Recent Development
    • 11.11 Pfizer Inc.
    • 11.12 Sanofi S.A.
    • 11.13 EMD Serono, Inc.
    • 11.14 Gilead Sciences Inc.
    • 11.15 Prometheus Therapeutics & Diagnostics
    • 11.16 Aduro BioTech
    • 11.17 Galena Biopharma
    • 11.18 Bavarian Nordic
    • 11.19 Celldex Therapeutics
    • 11.20 ImmunoCellular Therapeutics
    • 11.21 Incyte

    12 Future Forecast

    • 12.1 Immuno-oncology Drugs Market Forecast by Regions
      • 12.1.1 Global Immuno-oncology Drugs Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Immuno-oncology Drugs Revenue Forecast by Regions 2019-2025
    • 12.2 Immuno-oncology Drugs Market Forecast by Product
      • 12.2.1 Global Immuno-oncology Drugs Sales Forecast by Product 2019-2025
      • 12.2.2 Global Immuno-oncology Drugs Revenue Forecast by Product 2019-2025
    • 12.3 Immuno-oncology Drugs Market Forecast by End User
    • 12.4 North America Immuno-oncology Drugs Forecast
    • 12.5 Europe Immuno-oncology Drugs Forecast
    • 12.6 Asia Pacific Immuno-oncology Drugs Forecast
    • 12.7 Central & South America Immuno-oncology Drugs Forecast
    • 12.8 Middle East and Africa Immuno-oncology Drugs Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Immuno-oncology Drugs Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Immuno-oncology Drugs market is valued at 49200 million US$ in 2018 and will reach 142200 million US$ by the end of 2025, growing at a CAGR of 14.2% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Immuno-oncology Drugs market based on company, product type, end user and key regions.

      This report studies the global market size of Immuno-oncology Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Immuno-oncology Drugs in these regions.
      This research report categorizes the global Immuno-oncology Drugs market by top players/brands, region, type and end user. This report also studies the global Immuno-oncology Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Amgen, Inc
      AstraZeneca, Plc
      Bristol-Myers Squibb
      Celgene Corporation
      Eli Lilly and Company
      Merck & Co.
      Hoffmann-La Roche AG
      Johnson & Johnson
      Novartis International AG
      AbbVie, Inc.
      Pfizer Inc.
      Sanofi S.A.
      EMD Serono, Inc.
      Gilead Sciences Inc.
      Prometheus Therapeutics & Diagnostics
      Aduro BioTech
      Galena Biopharma
      Bavarian Nordic
      Celldex Therapeutics
      ImmunoCellular Therapeutics
      Incyte

      Market size by Product
      Immune Checkpoint Inhibitors
      Monoclonal Antibodies
      Cytokine-Based Immunotherapy
      Cancer Vaccines
      CAR-T Cell Therapy
      Market size by End User
      Hospitals
      Pharmacies
      Online Pharmacies

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Immuno-oncology Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Immuno-oncology Drugs market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Immuno-oncology Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Immuno-oncology Drugs submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Immuno-oncology Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Immuno-oncology Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now